Drug tolvaptan emergency acquisition.
Ended Awarded
- Contract number
- 36C24921N0266
- Awardee
-
Otsuka America Pharmaceutical Inc. UEI QKABLBMA8FT9
- Awarding agency
-
Veterans Integrated Service Network 9
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $10,102
Award facts
- Contract value 100% obligated
- $10,102.19 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
About this award
The U.S. Department of Veterans Affairs, Veterans Integrated Service Network 9, awarded a delivery order to Otsuka America Pharmaceutical Inc. on December 18, 2020, for an emergency acquisition of Tolvaptan (Jynarque) with a ceiling value of $10,102.19. This firm-fixed-price delivery order, with an ultimate completion date of December 30, 2020, was issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and performed in Potomac, Maryland. The contract includes no set-aside designation, reflecting Otsuka's status as an established pharmaceutical manufacturer. Tolvaptan is a specialized medication used to treat autosomal dominant polycystic kidney disease and hyponatremia, conditions requiring targeted pharmaceutical interventions for veterans.
This delivery order is part of a larger Indefinite Delivery Vehicle framework under which Otsuka America Pharmaceutical Inc. maintains substantial contract authority with the VA. The company holds a $83.3 million Blanket Purchase Agreement for Jynarque with the National Acquisition Center through March 26, 2026, as well as a $396 million Federal Supply Schedule contract for pharmaceuticals and hematology-related products. These vehicles enable the VA's network of integrated service networks across the country to efficiently procure critical specialty pharmaceuticals for veterans. The emergency acquisition reflects the VA's responsive procurement capability to address immediate pharmaceutical supply needs within its healthcare delivery system.
Quick answers
Who was awarded contract 36C24921N0266?
36C24921N0266 was awarded to Otsuka America Pharmaceutical Inc. by Veterans Integrated Service Network 9 (Veterans Health Administration) on December 18, 2020.
How much is contract 36C24921N0266 worth?
The government has obligated $10,102 on 36C24921N0266.
Is contract 36C24921N0266 an order under another contract?
Yes. 36C24921N0266 is a delivery order under 36F79720D0099, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24921N0266 competed?
The extent of competition for 36C24921N0266 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award